Antibody fragment-polymer conjugates and uses of same

• US 20090098147A1
• Filed: 11/12/2008
• Published: 04/16/2009
• Est. Priority Date: 01/21/1999
• Status: Active Grant

• Current Assignee: Gerardo Zapata, Iphigenia Koumenis, Steven Leong, Vanessa Hsei, Zahra Shahrokh
• Original Assignee: Gerardo Zapata, Iphigenia Koumenis, Steven Leong, Vanessa Hsei, Zahra Shahrokh
• Inventors: Shahrokh, Zahra, Koumenis, Iphigenia, Leong, Steven, Hsei, Vanessa, Zapata, Gerardo
• Granted Patent: US 7,842,789 B2
• Time in Patent Office: Days
• US Class Current: 424/178.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/6845 the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 17/02 Peptides being immobilised on, or in, an organic carrier
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/53 Hinge
• CPC Class Codes: C07K 2317/54 F(ab')2
• CPC Class Codes: C07K 2317/55 : Fab or Fab'
• CPC Class Codes: C07K 2317/56 : variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 : Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α₄β₇ integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.

Claims

1. A conjugate consisting essentially of an antibody fragment covalently modified by one or two nonproteinaceous polymer molecules at a free sulfhydryl group of a cysteine residue within the hinge region of the antibody fragment, wherein (a) the apparent molecular weight of the conjugate, as determined by size exclusion chromatography is at least 500 kD, (b) the average actual molecular weight of each nonproteinaceous polymer molecule is at least 20 kD, (c) the conjugate has an apparent size that is about 8-fold greater than the apparent size of the parental antibody fragment, (d) the conjugate binds the same antigen as the parental molecule that is not covalently modified by one or two nonproteinaceous polymer molecules, and wherein the antibody fragment comprises an antigen binding site that binds to a human tumor necrosis factor-α

(TNF-α

) polypeptide.

2. The conjugate of claim 1, wherein the apparent size of the conjugate is at least about 800 kD.

3. The conjugate of claim 1, wherein the apparent size of the conjugate is at least about 1,400 kD.

4. The conjugate of claim 1, wherein the apparent size of the conjugate is at least about 1,800 kD.

5. The conjugate of claim 1, wherein the apparent size of the conjugate is at least about 15 fold greater than the apparent size of at least one antibody fragment.

6. The conjugate of claim 5, wherein the apparent size of the conjugate is at least about 25 fold greater than the apparent size of at least one antibody fragment.

7. The conjugate of claim 1 wherein the antibody fragment is selected from the group consisting of Fab, Fab′

, Fab′

-SH, Fv, scFv and F(ab′

)₂.

8. The conjugate of claim 7 wherein the antibody fragment is selected from the group consisting of Fab, Fab′

and Fab′

-SH.

9. The conjugate of claim 7 wherein the antibody fragment is a F(ab′

)₂ fragment.

10. The conjugate of claim 7 wherein the antibody fragment is a Fab′

fragment.

11. The conjugate of claim 1 wherein the antibody fragment is attached to no more than 1 nonproteinaceous polymer molecule.

12. The conjugate of claim 7 wherein the antibody fragment is covalently attached to no more than 1 nonproteinaceous polymer molecule.

13. The conjugate of claim 9 wherein the antibody fragment is covalently attached to no more than 1 nonproteinaceous polymer molecule.

14. The conjugate of claim 10 wherein the antibody fragment is covalently attached to no more than 1 nonproteinaceous polymer molecule.

15. The conjugate of claim 1 wherein at least one nonproteinaceous polymer is a polyethylene glycol (PEG).

16. The conjugate of claim 15 wherein the PEG has an average molecular weight of at least about 20 kD.

17. The conjugate of claim 15 wherein the PEG has an average molecular weight of at least about 40 kD.

18. The conjugate of claim 15 wherein the PEG is a single chain molecule.

19. The conjugate of claim 15 wherein the PEG is a branched chain molecule.

20. The conjugate of claim 15, wherein the antibody fragment is selected from the group consisting of Fab, Fab′

, Fab′

-SH, Fv, scFv and F(ab′

)₂ and is covalently attached to no more than one PEG molecule.

21. The conjugate of claim 15, wherein the antibody fragment is selected from the group consisting of Fab, Fab′

and Fab′

-SH and is covalently attached to no more than one PEG molecule.

22. The conjugate of claim 1, wherein the antibody fragment is selected from the group consisting of Fab, Fab′

and Fab′

-SH, wherein the antibody fragment is covalently attached to no more than one nonproteinaceous polymer molecule, and wherein the nonproteinaceous polymer molecule is a PEG having an average molecular weight of at least about 20 kD.

23. The conjugate of claim 22 wherein the PEG has an average molecular weight of at least about 30 kD.

24. The conjugate of claim 22 wherein the PEG has an average molecular weight of at least about 40 kD.

25. The conjugate of claim 22 wherein the PEG is a single chain molecule.

26. The conjugate of claim 22 wherein the PEG is a branched chain molecule.

27. The conjugate of claim 1 wherein the antibody fragment comprising the antigen binding site is humanized.

28. The conjugate of claim 1, wherein the covalent structure of the conjugate is free of any matter other than the antibody fragment and nonproteinaceous polymer molecules that form the conjugate.

29. The conjugate of claim 1, wherein the covalent structure of the conjugate incorporates one or more nonproteinaceous labels, and wherein the covalent structure of the conjugate is free of any matter other than the antibody fragment, nonproteinaceous polymer and nonproteinaceous label molecules that form the conjugate.

30. The conjugate of claim 29 wherein at least one nonproteinaceous label is a radiolabel.

31. A composition comprising the conjugate of claim 1 and a carrier.

32. The composition of claim 31 that is sterile.

33. A method of treating an inflammatory disorder in a mammal comprising administering to the mammal an effective amount of the conjugate of claim 1.

34. The method of claim 33 wherein the inflammatory disorder is Crohn'"'"'s disease.

35. The method of claim 33 wherein the inflammatory disorder is inflammatory bowel disease.

36. The method of claim 33 wherein the inflammatory disorder is rheumatoid arthritis.